PATH Malaria Vaccine Initiative

Phase 3 malaria vaccine trial begins—final testing of RTS,S

African research centers partner with GlaxoSmithKline Biologicals and MVI
Read more »

Trial participants and their mothers with Dr. Salim Abdulla and vaccination staff at the Bagamoyo Research and Training Centre

Partnering with us

We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

We support a diversity of malaria vaccine candidates at different stages of development.

View the vaccine portfolio »

What we do and how we do it

MVI provides funding and technical support to partners worldwide to accelerate the development of malaria vaccines. MVI also works to ensure that malaria vaccines will reach those who need them.
Find out more »

Photo: MVI/ David Poland
Trial participants and their mothers (on bench) with Dr. Salim Abdulla (standing left) and vaccination staff at the Bagamoyo Research and Training Centre of the Ifakara Health Institute (IHI) in Tanzania.

News and announcements

Phase 1 trial of whole-parasite malaria vaccine begins

In a move that highlights the strength of public-private collaboration in tackling international health challenges, the Maryland-based company Sanaria Inc., with support from MVI, has initiated a Phase 1 clinical trial—the first tests in adult volunteers—of its unique malaria vaccine candidate.
Read more »

Preparing for Malaria Vaccines: African Scientists Speak Out

Researchers and scientists working on new health interventions can help to close the costly gap between the availability of life-saving interventions and developing countries' access to them. In this video, scientist-advocates describe their critical role in closing the gap.
Watch the video »